Condition: PTSD · Sponsor: White River Junction Veterans Affairs Medical Center
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
This description comes directly from the study's public registry record.
Bradley V Watts, MD, MPH · 802-295-9363 · bradley.watts@va.gov
Emily Colon, MS · 802-295-9363 · emily.colon@va.gov
Always discuss trial participation with your own doctor first.
| White River Junction VAMC | White River Junction, Vermont, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05637879